

Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018

November 27 2017

Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment has been accepted for presentation at ASCO-GI 2018, taking place 18-20th of January in San Francisco, USA. The accepted abstract describes interim results from the ongoing ISO-CC-005 study in which Modufolin® is administered in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab.

Isofol Medical AB (publ) announces that an abstract has been accepted for presentation at next year's Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO). The conference will take place on 18-20th of January in San Francisco and is a specialized oncology event designed to provide scientific and educational content for physicians and researchers within the GI community. The abstract will be released by ASCO on January 16 at 5:00 PM EST on meetinglibrary.asco.org.

The approved abstract describes interim results from Isofol's ongoing multi-center, phase I/II study ISO-CC-005 in metastasizing colorectal cancer patients, where efficacy was evaluated as ORR (Objective Response Rate) after 4 cycles of chemotherapy. The study primarily investigates safety and tolerability of Modufolin® at 4 dose levels in patients that are eligible for 5-FU/folate therapy alone or in combination with irinotecan or oxaliplatin ± bevacizumab.

For more information, please contact:

Anders Rabbe, CEO, Isofol Medical AB
E-mail: anders.rabbe@isofolmedical.com
Phone: +46 (0)707 646 500

Karin Ganlöv, CMO, Isofol Medical AB
E-mail: karin.ganlov@isofolmedical.com
Phone: +46 (0) 702 433 750

About Modufolin®

Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study.

About Isofol Medical AB

Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

www.isofol.se